Results 1 to 10 of about 114,758 (340)

Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial) [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundThere is still uncertainty about the safety of aprotinin for coronary artery bypass graft surgery. The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral versus single internal thoracic artery grafting. Many
Umberto Benedetto, Douglas G. Altman, Stephen Gerry, Alastair Gray, Belinda Lees, Gianni D. Angelini, Marcus Flather, David P. Taggart   +7 more
doaj   +10 more sources

Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and ε-aminocaproic acid -- a meta-analysis of randomised and observational trials of over 30.000 patients. [PDF]

PLoS ONE, 2013
BackgroundTo compare the effect of aprotinin with the effect of lysine analogues (tranexamic acid and ε-aminocaproic acid) on early mortality in three subgroups of patients: low, intermediate and high risk of cardiac surgery.Methods and findingsWe ...
Patrick Meybohm, Eva Herrmann, Julia Nierhoff, Kai Zacharowski   +3 more
doaj   +5 more sources

Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo

Scientific Reports, 2021
Influenza viruses cause significant morbidity and mortality worldwide. Long-term or frequent use of approved anti-influenza agents has resulted in drug-resistant strains, thereby necessitating the discovery of new drugs. In this study, we found aprotinin,
Eun-Jung Song, Erica Españo, Sang-Mu Shim, Jeong-Hyun Nam, Jiyeon Kim, Kiho Lee, Song-Kyu Park, Chong-Kil Lee, Jeong-Ki Kim   +8 more
doaj   +2 more sources

Aprotinin Inhibits SARS-CoV-2 Replication

Cells, 2020
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S ...
Denisa Bojkova, Marco Bechtel, Katie-May McLaughlin, Jake E. McGreig, Kevin Klann, Carla Bellinghausen, Gernot Rohde, Danny Jonigk, Peter Braubach, Sandra Ciesek, Christian Münch, Mark N. Wass, Martin Michaelis, Jindrich Cinatl   +13 more
doaj   +2 more sources

Aprotinin treatment against SARS‐CoV‐2: A randomized phase III study to evaluate the safety and efficacy of a pan‐protease inhibitor for moderate COVID‐19

European Journal of Clinical Investigation, 2022
SARS‐CoV‐2 virus requires host proteases to cleave its spike protein to bind to its ACE2 target through a two‐step furin‐mediated entry mechanism. Aprotinin is a broad‐spectrum protease inhibitor that has been employed as antiviral drug for other human ...
Francisco Javier Redondo Calvo, Juan Fernando Padin Nogueira, José Ramón Muñoz-Rodríguez   +2 more
exaly   +2 more sources

Aprotinin in high-risk isolated coronary artery bypass graft patients: a 3-year propensity matched study [PDF]

Journal of Cardiothoracic Surgery
Background Aprotinin, a serine protease inhibitor, has been used variably in cardiac surgery amidst ongoing debates about its safety following several previous studies.
Rishab Makam, Ayush Balaji, Marwan Al Munaer, Shantanu Bajaj, Nabil Hussein, Mahmoud Loubani   +5 more
doaj   +2 more sources

Increased perioperative mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgery

Intensive Care Medicine, 2013
G. Walkden, V. Verheyden, R. Goudie, G. Murphy   +3 more
exaly   +2 more sources

Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor

TH Open, 2021
Background Aprotinin is a broad-acting serine protease inhibitor that has been clinically used to prevent blood loss during major surgical procedures including cardiac surgery and liver transplantation.
Ton Lisman, Jelle Adelmeijer, Dana Huskens, Joost C. M. Meijers   +3 more
doaj   +1 more source

Use and safety of aprotinin in routine clinical practice

European Journal of Anaesthesiology, 2022
BACKGROUND Aprotinin has been used to reduce blood loss and blood product transfusions in patients at high risk of major blood loss during cardiac surgery.
S. D. De Hert, A. Ouattara, D. Royston, Jan van der Linden, K. Zacharowski   +4 more
semanticscholar   +1 more source

Therapeutic use of α2-antiplasmin as an antifibrinolytic and hemostatic agent in surgery and regenerative medicine

npj Regenerative Medicine, 2022
The biomaterial fibrin is widely used as a clinical tissue sealant in surgery. In preclinical research, fibrin is also extensively studied as a carrier material for growth factor delivery.
Jialu Liu, Ani Solanki, Michael J. V. White, Jeffrey A. Hubbell, Priscilla S. Briquez   +4 more
doaj   +1 more source